Oncotarget

Research Papers:

XRCC1 serves as a potential prognostic indicator for clear cell renal cell carcinoma and inhibits its invasion and metastasis through suppressing MMP-2 and MMP-9

Qing-Hua Liu, You Wang, Hong-Mei Yong, Ping-Fu Hou, Jie Pan, Jin Bai _ and Jun-Nian Zheng

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:109382-109392. https://doi.org/10.18632/oncotarget.22680

Metrics: PDF 1158 views  |   HTML 1777 views  |   ?  


Abstract

Qing-Hua Liu1,2,*, You Wang3,*, Hong-Mei Yong4,*, Ping-Fu Hou1, Jie Pan1,7, Jin Bai1 and Jun-Nian Zheng1,5,6

1Jiangsu Key Laboratory of Biological Cancer Therapy, Xuzhou Medical University, Xuzhou 221002, Jiangsu Province, China

2Department of Pathology, Xuzhou Medical University, Xuzhou 221002, Jiangsu Province, China

3Department of Obstetrics and Gynecology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, China

4Department of Medical Oncology, Huai’an Hospital to Xuzhou Medical University, Huai’an 223001, Jiangsu Province, China

5Jiangsu Center for The Collaboration and Innovation of Cancer Biotherapy, Cancer Institute, Xuzhou Medical University, Xuzhou 221002, Jiangsu Province, China

6Center of Clinical Oncology, Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, Jiangsu Province, China

7Department of Clinical Oncology, Pizhou people's Hospital, Xuzhou 221002, Jiangsu Province, China

*These authors have contributed equally to this work

Correspondence to:

Jin Bai, email: [email protected]

Jun-Nian Zheng, email: [email protected]

Keywords: XRCC1; renal cell carcinoma; metastasis; prognostic biomarker; MMPs

Received: June 22, 2017     Accepted: November 03, 2017     Published: November 25, 2017

ABSTRACT

X-ray repair cross-complementing group 1 (XRCC1) is a major DNA repair gene that is responsible for fixing DNA base damage and single-strand breaks by interacting with DNA components at the damage site. This study explored the clinical significance of XRCC1 in human clear cell renal cell carcinoma (ccRCC) and further examined the mechanism of the role of XRCC1 in ccRCC. The clinical relevance of XRCC1 in ccRCC was evaluated using tissue microarrays and immunohistochemical staining of two independent human ccRCC cohorts. Our data demonstrated that XRCC1 expression was dramatically decreased in ccRCC tissues compared with that in normal renal tissues and paired adjacent non-tumor tissues. Low XRCC1 expression was significantly correlated with lymph node metastasis and with worse overall and disease-specific survival in patients, as determined by log-rank tests. However, Cox regression analysis revealed that XRCC1 expression was not an independent prognostic factor in ccRCC patients. Furthermore, XRCC1 suppressed ccRCC migration and invasion by inhibiting MMP-2 and MMP-9 expression through the regulation of TIMP-2 and TIMP-1. These findings indicated that decreased XRCC1 expression was associated with lymph node metastasis but was not an independent prognostic factor in ccRCC patients. XRCC1 may serve as a potential therapeutic target for inhibiting ccRCC metastasis but cannot be used as an independent prognostic factor.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 22680